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Epidemic infections have frightened and
harmed people for millennia. Plague (1)
and typhus (2), bacterial infections as-
sociated with poor sanitation and high
mortality, have devastated populations.
Both still reappear intermittently, but
they are generally contained with better
sanitation and control of rodent and insect
vectors along with antibiotics. In contrast,
viral epidemics persist. A unique strain of
influenza caused a global epidemic (pan-
demic) in 1918 resulting in millions of
deaths (3). Among recent outbreaks of
viral infections, several have been caused
by coronaviruses (4). One of these, severe
acute respiratory syndrome coronavirus 2
(SARS-CoV-2), is now causing a pandemic
illness termed coronavirus disease 2019
(COVID-19) that poses unique challenges.
This novel coronavirus is readily trans-
mitted from person-to-person, even by
thosewho are infected butwithout symp-
toms. In susceptible people it causes
severe illness and often death from
pulmonary and systemic injuries. At pres-
ent, we have neither a preventive vaccine
nor well-studied pharmacotherapy, al-
though work to develop these is vigor-
ously underway.
Certain groups are more vulnerable to
COVID-19, notably older people and those
with underlying medical conditions. Be-
cause diabetes is one of the conditions
associated with high risk, the diabetes
community urgently needs to know more
about COVID-19 and its effects on people
with diabetes.
Between the first appearance of this
illness in December 2019 and the time
of writing this commentary, several de-
tailed clinical descriptions have been
published. Among 44,672 patients in
China with infection confirmed by nu-
cleic acid testing up to mid-February
(5), most (87%) were between 30 and
79 years old. A large majority (81%)
were considered to have mild illness,
but in 14% itwas judged tobe severe and
in 5% critical. Of all confirmed cases,
2.3% of patients died. Higher mortality
rates were found among those $80
years old (14.8%), in those with preex-
isting cardiovascular disease (10.5%),
and in men (2.8%) as compared with
women (1.7%). Among people with di-
abetes the mortality rate was 7.3%,
more than three times that of theoverall
population. Two other conditions that
are common in thosewithdiabeteswere
also associated with higher mortality
rates: 10.5% for cardiovascular disease
and 6.0% for hypertension. Because mor-
tality rates were not stratified by age, it is
not clear how much of the excess risk in
people with these conditions was inde-
pendently related to age.
Another report included clinical data
collected up to the end of January for
1,099 patients hospitalized with labora-
tory-confirmed infection in China (6). By
far the most common symptoms on ad-
mission were fever and cough, and a
majority had radiologic evidence of pul-
monary disease. Of all patients hospital-
ized,6.1%met the compositeprimaryend
point, a requirement for intensive care or
mechanical ventilation, or died. The prev-
alenceofdiabetes in thewholepopulation
was 7.4%, but 27% of those meeting the
primary endpoint haddiabetes. The over-
all mortality rate was 1.4%.
A third Chinese report described the
clinical features and outcomes of 191
patients hospitalized with a confirmed
diagnosis and complete information re-
garding outcomes (7). Nearly half had
a preexisting illness and 19% a diagnosis
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of diabetes. The overall mortality rate
was 28%. Multivariable analysis sug-
gested that older age, early evidence of
organ failure, and a D-dimer level .1
mg/L on admission were significant risk
factors for in-hospital mortality.
A case in the U.S. was confirmed in
January 2020 in Washington State. This
35-year-oldmanwas a local residentwho
had recently traveled to China (8). Soon
after, a case in a long-term care facility
was identified, a73-year-oldwomanwith
diabetes, obesity, hypertension, and car-
diovascular disease who ultimately suc-
cumbed to the infection (9). The disease
propagated in residents, visitors, and
health care personnel at the facility and
later elsewhere in the community. Two
series of cases admitted to intensive care
units inWashingtonStatewithconfirmed
COVID-19 were reported (10,11). In one,
7 of 21 patients had known diabetes,
and at the time of the report 67% of
the cohort had died and 24% were still
in critical condition (10). In the other,
14 of the 24 patients had diabetes and
half of the whole group died during the
period of observation (11). Data from
the U.S. as a whole are being collected
by the Centers for Disease Control and
Prevention. As of 28 March, more than
74,000 COVID-19 cases had been con-
firmed. Within a subgroup of 7,162 pa-
tients for whom complete data on
underlying health conditions were avail-
able, diabetes was not more frequent
than reported in the general population.
However, among those with COVID-19,
diabetes was reported in 6% of those
not hospitalized, 24% of those hospital-
ized but not in intensive care, and 32%
of those admitted to an intensive care
unit (12).
These previous analyses of popula-
tions in China with varying severity of
illness and clinical outcomes and early
reports from the U.S. offer important
insights. The rapid accumulation of cases
in the first 3 months after recognition of
this viral syndrome testifies to its high
transmission rate. The mortality figures
verify how dangerous COVID-19 can be,
and the demonstration of increased risk
in older people and those with diabetes
and other comorbidities calls for special
attention to these groups.
A group of articles recently accepted
by Diabetes Care focuses specifically
on COVID-19 in people with diabetes
(13–19). Shi et al. (13) compared the
characteristics and outcomes of individ-
uals with diabetes with those of equal
numbers of people without diabetes
matched for sex and age. They analyzed
data from 153 people with diabetes
comprising 9.8% of a Chinese population
that was hospitalized between 1 January
and 8 March 2020 with confirmed COVID-
19. Themedian agewas64years and49%
were men. Their duration of symptoms
prior to hospitalization did not differ
from the comparator group and present-
ing symptomswere similar, but PaO2was
lower on admission. In-hospitalmortality
was 20% compared with 10.5% for those
without diabetes. Within the group with
diabetes, unadjusted comparisons of ini-
tial characteristics of those with diabetes
who died and survivors showed many
differences, including older age, more
frequent history of hypertension or car-
diovascular disease, and higher glucose,
creatinine, and C-reactive protein levels.
Multivariable modeling of data from
those with diabetes suggested older
age and hypertension were indepen-
dently associated with mortality.
Two reports examined the association
of obesity, an emerging risk factor for
severe illness in COVID-19, with out-
comes. Cai et al. (14) divided 383patients
hospitalized with confirmed COVID-19
into groups considered to be under-
weight (n 5 16), of normal weight
(n 5 203), overweight (n 5 123), or
obese (n 5 41) according to thresholds
for BMI used in Asian populations. Com-
pared with the normal weight subgroup,
those who were obese did not differ in
age or duration of symptoms but had
higher rates of diabetes (7.3% vs. 5.4%)
or hypertension (22% vs. 14%). After
adjustment for these and other clini-
cal features, progression to severe ill-
ness (defined as respiratory rate .30
breaths/min, resting oxygen saturation
#93%, PaO2/fraction of inspired oxygen
[FiO2]#300mmHg, or need for intensive
care) was more frequent in the obese
group than the normal weight group
(odds ratio [OR] 3.40 [95% CI 1.40–
2.86]). This observation is supported
by the findings of Gao et al. (15) in
75 Chinese patients hospitalized with
confirmed infection who were consid-
ered obese (BMI $25 kg/m2) and were
matchedwith75nonobese individualsby
age and sex. After adjustment for clinical
characteristics including the presence of
diabetes, the obese group had threefold
greater likelihood (OR 3.00, 95% CI 1.22–
7.38) of progressing to severe/critical
status. A nearly linear relationship be-
tween higher BMI and severe/critical
illness was demonstrated in the whole
cohort.
Chen et al. (16) studied mortality
among people with diabetes compared
with those without diabetes and investi-
gated whether the type of prior glucose-
lowering therapy was associated with
outcomes among people with diabetes.
They analyzed data from 904 patients
hospitalized with either a laboratory or
clinical diagnosis of infection, of whom
15% had diabetes. Mortality rates in
those with diabetes were two to three
times higher than in those without di-
abetes.Multivariable analyseswithin the
subgroup with diabetes identified older
age and higher C-reactive protein as
independentpredictors of death. Further
analyses suggested that use of insulin
was associated with worse outcomes.
Whether this was due to effects of in-
sulin itself or to characteristics of the
patients for whom it was prescribed is
not clear.
Yet another question of interest is
whether levels of glycemic control cor-
relate with progression to severe illness.
This question was addressed by Sardu
et al. (17) in 59 patients hospitalizedwith
confirmed COVID-19, of whom 26 had
previously diagnoseddiabetes and33did
not. Some of the patients in each group
received intravenous insulin infusion to
control hyperglycemia, whereas others
did not. In a multivariable analysis with
adjustment for clinical risk factors, the
risk of progression to severe illness was
lower among those given intravenous
insulin. The findings of this unrandom-
ized comparison were interpreted as
suggesting that insulin infusion may im-
prove outcomes. If the benefits of seek-
ing excellent glycemic control by this
means are confirmed, close monitoring
of glucose levelswill be essential. Success
in adapting systems for continuous glu-
cose monitoring to remote surveillance
by intensive care unit teams was re-
ported by Shenav-Zaltzman et al. (18)
in a small number of patients.
Finally, Rao et al. (19) used Mende-
lian randomization to assess possible
associations of various medical condi-
tions and traits with expression of
angiotensin-converting enzyme 2 (ACE2).
This molecule may be a site of attachment
of the virus responsible for COVID-19 to
cells in the lung and elsewhere. They
concluded that “diabetes and related
traits may increase ACE2 expression,
which may influence susceptibility to
infection (or more severe infection).”
Such observationsdwhich are clearly
provocative but not definitivedpose
the possibility that increased ACE2 in
diabetes could mediate increased vul-
nerability. It has been suggested that
widely used medicines affecting the renin-
angiotensin-aldosterone systemmay have
either harmful or favorable effects on
COVID-19 infections (20,21), but no de-
finitive evidence to support either hy-
pothesis is yet available.
There is much here to digest. The data
reported in these articles were rapidly
collected and analyzed, in most cases
under urgent and stressful conditions.
Thus, some of the analyses are under-
standably limited due to missing data,
incomplete follow-up, and inability to
identify infected but asymptomatic pa-
tients. Even so, somepoints are clear. The
consistency of findings in these rapidly
published reports is reassuring in terms
of scientific validity, but the story un-
folding is worrisome. Diabetes has not
yetbeenshownto increase the likelihood
of infection, but progression to severe
illness is more likely in people with di-
abetes. The frequencyof diabetes among
patients requiring intensive care is two to
three times higher than in the overall
population, and mortality rates in those
with diabetes are also higher. Neither the
mechanisms underlying the increased
risk nor the best interventions to limit
it have yet been defined, but the studies
in this collection of articles offer impor-
tant clues. Obesity is a major risk factor
for diabetes and appears to be an in-
dependent risk factor for severe illness
in COVID-19. Rates of severe illness
are therefore likely to be especially fre-
quent in regions and populations where
both obesity and diabetes are common.
Because more severe hyperglycemia ac-
companies progression to severe pul-
monary and systemic illness, better
metabolic control with insulin infusion
or other means may be protective. Com-
plications of diabetes including renal,
cardiac, and peripheral vascular disease
can be additive risk factors and call
for specific attention. Some circulating
markers of systemic inflammation are
elevated in severe cases, suggesting
possiblemolecular sites for intervention.
Of particular interest is the observation
that ACE2 expression is associated with
diabetes andmay be involved in this viral
infection, offering another starting point
for research to develop specifically tar-
geted interventions.
These observations suggest there is
work for all of us. People with diabetes
should be more attentive than others to
self-protectiveactions, particularlyhand-
washing and physical distancing. An ad-
equate supply of insulin and self-care
supplies is essential when sheltering in
place. Medical providers and health sys-
tems can help by assuring reliable access
to tools for diabetes self-management.
Hospital providers should all know that
more severe respiratory illness is asso-
ciated with diabetes. In-hospital meta-
bolic control may be more difficult when
caregivers need personal protective equip-
ment, but newer methods of remotely
monitoring glucose patterns could be
uniquely helpful. Researchers and clini-
cians are called upon to follow the clues
and find specific interventions. As ex-
amples, three additional articles in the
current collection in Diabetes Care of-
fer expert assessments of important
challenges and opportunities posed by
COVID-19 (22–24).
TheCOVID-19epidemic challenges the
entire diabetes community, but the re-
sponse has been encouraging. As the
scale and severity of COVID-19 have
become widely known, there has been
an outpouring of support for those af-
flicted. Medical personnel and others
on the front lines have shown courage
and determination. Virtual interactions,
whether on an individual or group basis,
are now routine. Health care providers
can use this technology to guide the care
of their patients, while clinical research-
ers continue ongoing studies andprovide
vital medications to study participants.
Digital technologies are providing re-
mote access to educational and research
meetings and, of course, to loved ones
and friends who may be otherwise in-
accessible. Until a proven vaccine and
highly effective pharmacotherapy are
developed, we need widespread test-
ing of apparently well individuals to de-
termine who has immunity from prior
infection, who is at risk, and who is
unknowingly infected. As the peak of
COVID-19 begins to pass and we work
toobtainbetter testing, pharmacotherapy,
and ultimately a vaccine, we will enter
a longer interval in which we must con-
tinue to support the most vulnerable
populationsdespeciallyolderpeople, those
with diabetes or obesity, and those
who lack the resources to limit day-to-
day exposure to infection. We hope a
growing sense of community will help in
this task.
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